Terns Pharmaceuticals Q2 2025 Earnings Report

Terns Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.29
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Terns Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Terns Pharmaceuticals Announcement Details

• Quarter: Q2 2025
• Date: 8/4/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, August 7, 2025
• Conference Call Time: 4:00PM ET

Terns Pharmaceuticals (NASDAQ:TERN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for liver diseases. Headquartered in San Diego, California, Terns focuses on addressing unmet needs in metabolic and cholestatic liver disorders as well as viral hepatitis. The company’s research platform leverages proprietary bile acid chemistry and nuclear hormone receptor modulation to advance compounds with the potential to alter disease pathways in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and chronic hepatitis B virus (HBV) infection.

Terns’ lead programs include TERN-201, a proprietary norursodeoxycholic acid (norUDCA) derivative engineered to improve cholestatic liver function in PSC and PBC, and TERN-301, an oral capsid assembly inhibitor targeting HBV replication. Additional pipeline candidates such as TERN-501, a selective farnesoid X receptor (FXR) agonist, and other bile acid–based analogs are in preclinical or early clinical development for NASH and related metabolic liver conditions. By combining structure-based drug design with in vivo models of liver disease, the company aims to deliver differentiated assets capable of improving key biochemical and histologic measures of liver health.

Founded in 2018, Terns Pharmaceuticals completed its initial public offering on the Nasdaq exchange in 2021 under the ticker symbol TERN. The company’s executive team is led by President and Chief Executive Officer Helen Gao, Ph.D., whose background spans small-molecule drug discovery and clinical development in hepatology. Terns collaborates with leading academic centers in North America and Europe to support its clinical trials and regulatory efforts. With a global focus on liver disease patients, the company plans to advance its portfolio through proof-of-concept studies and to forge partnerships aimed at broadening patient access worldwide.